<DOC>
	<DOCNO>NCT01496989</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability immunogenicity multiantigen HIV ( HIV-MAG ) plasmid DNA ( pDNA ) vaccine co-administered recombinant human IL-12 pDNA ( GENEVAX® IL-12 ) follow preceded recombinant Ad35-GRIN/ENV HIV vaccine low-risk HIV-uninfected healthy adult .</brief_summary>
	<brief_title>Safety Immunogenicity Study HIV-MAG Vaccine +/- IL-12 Ad35-GRIN/ENV HIV-uninfected Volunteers</brief_title>
	<detailed_description>The study randomize , double-blind placebo-controlled trial assess safety tolerability HIV-MAG without co-administered GENEVAX® IL-12 give intramuscularly vivo electroporation ( IM/EP ) use Ichor Medical Systems TriGrid Delivery System ( TDS-IM ) follow Ad35-GRIN/ENV four different regimen . An additional group evaluate safety tolerability Ad35-GRIN/ENV follow HIV-MAG co-administered GENEVAX® IL-12 give intramuscularly vivo electroporation ( IM/EP ) use Ichor Medical Systems TriGrid Delivery System ( TDS-IM ) . Volunteers screen 42 day 1st vaccination follow 12 month first vaccine administration . It anticipate take approximately 3 month enrol study . Approximately 75 volunteer ( 60 vaccine/15 placebo recipient ) include study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>healthy male female adult , 18 50 year age ( 21 50 year age volunteer Rwanda ) , report highrisk behaviour HIV infection , available duration trial , willing undergo HIV testing , use effective method contraception , , opinion principal investigator designee , understand study provide write informed consent . Principal exclusion criterion : confirm HIV infection , pregnancy lactation , significant acute chronic disease , clinically significant laboratory abnormality , recent vaccination receipt blood product , previous receipt HIV vaccine , previous severe local systemic reaction vaccination history severe allergic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>HIV vaccine</keyword>
	<keyword>HIV prevention</keyword>
</DOC>